bpc 157 peptide doses dosage chart MOTS-C Chart: Protocol Guide for Metabolic Health & Performance Dosing Guide – bpc 157 peptide dosing guide

If a patient is already nauseated on tirzepatide and adds a peptide that may cause its own GI symptoms, the combined burden can push them off therapy entirely

Phase 2b clinical trials conducted on 300 obese test subjects in Australia observed that the peptide appeared to result in consistent weight loss over 12 weeks when introduced once daily

Key Research Applications Obesity and weight management models Lipolysis optimisation Metabolic health and energy balance Anti-catabolic muscle protection Synergy with metabolic peptides Preparation & Storage Reconstitute with bacteriostatic water (room temperature first to ensure dissolution)

If you have access to tirzepatide, it is the superior GLP-1 class option for combination with AOD 9604

Mechanism of Action (Based on Preclinical and Clinical Research): Mimics endogenous GHRH by binding to pituitary GHRH receptors Stimulates pulsatile secretion of GH, preserving physiological release patterns Increases circulating IGF-1 levels, mediating many of its metabolic and anabolic effects Supports lipolysis and lipid redistribution via GH/IGF-1 axis modulation Potential Benefits (Based on Preclinical Research): Enhanced growth hormone and IGF-1 activity in research models Studied for effects on reducing visceral adipose tissue (VAT) Investigated for improvements in body composition and metabolic regulation Potential research applications in models of age-related decline in GH secretion For Research Use Only

[1] mhra.gov.uk or via the Yellow Card app)